Table 1.

Outcomes for each treatment resulting from the different NN PS matching techniques (k = 5).

Product	PS NN techn.	ATE ($\overline{\mathit{S}{\mathit{G}}^{\mathit{s}}}$, months)	$\stackrel{\mathit{ˆ}}{\mathit{V}}$	$\overline{{\mathit{V}}^{\mathit{s}}}$	$\mathit{var}({\mathit{V}}^{\mathit{s}})$	C
Bevacizumab (2784 patients)	1:5	8.00	567.51	310.21	2.45e + 5	4.6%
	weighted 1:5	7.97	566.04	312.30	2.51e + 5	4.6%
	5 bootstrap	7.39	600.79	282.97	2.35e + 5	5.2%
Cetuximab (845 patients)	1:5	7.38	477.96	261.86	1.54e + 5	1.8%
	weighted 1:5	7.31	482.54	264.88	1.56e + 5	1.8%
	5 bootstrap	6.33	534.84	293.23	2.18e + 5	2.5%
Panitumumab (308 patients)	1:5	11.25	359.27	282.25	2.48e + 5	1.6%
	weighted 1:5	10.96	329.42	309.92	2.60e + 5	1.6%
	5 bootstrap	9.71	453.27	276.24	2.75e + 5	1.6%
Aflibercept (31 patients)	1:5	2.28	323.71	424.96	3.16e + 5	23%
	weighted 1:5	2.56	320.35	428.04	3.32e + 5	23%
	5 bootstrap	3.18	340.35	337.58	2.50e + 5	19%